Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action

Geming Li, Su Hua Sha, Elena Zotova, Joseph C. Arezzo, Thomas R. Van De Water, Jochen Schacht

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Salicylate has recently been demonstrated to protect against the auditory and vestibular side effects of aminoglycoside antibiotics. Similarities in the toxic mechanisms suggest salicylate as a treatment strategy to prevent the ototoxic side effects of cisplatin (CDDP). We first tested protection of the inner ear in Wistar rats receiving a single infusion of 16 mg CDDP/kg body weight with or without treatment with 100 mg/kg salicylate (bid) for 5 days beginning one day before the CDDP infusion. Cisplatin induced a threshold shift of more than 30 dB (at 14 kHz; measured by auditory evoked brain stem response) that was significantly reduced by salicylate. We then examined the protective potential of salicylate on the cochlea, peripheral nerves, and kidney in a rat model of breast cancer-Fisher344 rats implanted with highly metastatic MTLn3 breast cancer cells. Animals received 3 × 5 mg CDDP/kg (given every third day), and salicylate was administered at 100 mg/kg (bid) from 2 days before to 3 days after CDDP treatment. Salicylate significantly attenuated the CDDP-induced threshold shift from approximately 20 dB (at 16 and 24 kHz) to approximately 5 dB, and drastically reduced the loss of cochlear outer hair cells. Likewise, salicylate protected kidney function (measured as plasma blood urea nitrogen and creatinine levels) from CDDP toxicity. Protection of nerve conduction velocities of both sensory and motor nerves was minimal. The chemotherapeutic efficacy of CDDP on suppression of tumor mass and cancer cell metastasis remained unaffected by salicylate. The results suggest that administration of salicylate may become the basis of an effective therapeutic intervention against the ototoxic and nephrotoxic side effects associated with CDDP chemotherapy.

Original languageEnglish (US)
Pages (from-to)585-596
Number of pages12
JournalLaboratory Investigation
Volume82
Issue number5
DOIs
StatePublished - 2002

Fingerprint

Salicylates
Cisplatin
Hearing
Kidney
Outer Auditory Hair Cells
Breast Neoplasms
Brain Stem Auditory Evoked Potentials
Poisons
Blood Urea Nitrogen
Neural Conduction
Cochlea
Aminoglycosides
Inner Ear
Therapeutics
Peripheral Nerves
Wistar Rats
Creatinine
Neoplasms
Body Weight
Neoplasm Metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. / Li, Geming; Sha, Su Hua; Zotova, Elena; Arezzo, Joseph C.; Van De Water, Thomas R.; Schacht, Jochen.

In: Laboratory Investigation, Vol. 82, No. 5, 2002, p. 585-596.

Research output: Contribution to journalArticle

Li, Geming ; Sha, Su Hua ; Zotova, Elena ; Arezzo, Joseph C. ; Van De Water, Thomas R. ; Schacht, Jochen. / Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. In: Laboratory Investigation. 2002 ; Vol. 82, No. 5. pp. 585-596.
@article{5bf3d87c9781485084d2c9084eea86ec,
title = "Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action",
abstract = "Salicylate has recently been demonstrated to protect against the auditory and vestibular side effects of aminoglycoside antibiotics. Similarities in the toxic mechanisms suggest salicylate as a treatment strategy to prevent the ototoxic side effects of cisplatin (CDDP). We first tested protection of the inner ear in Wistar rats receiving a single infusion of 16 mg CDDP/kg body weight with or without treatment with 100 mg/kg salicylate (bid) for 5 days beginning one day before the CDDP infusion. Cisplatin induced a threshold shift of more than 30 dB (at 14 kHz; measured by auditory evoked brain stem response) that was significantly reduced by salicylate. We then examined the protective potential of salicylate on the cochlea, peripheral nerves, and kidney in a rat model of breast cancer-Fisher344 rats implanted with highly metastatic MTLn3 breast cancer cells. Animals received 3 × 5 mg CDDP/kg (given every third day), and salicylate was administered at 100 mg/kg (bid) from 2 days before to 3 days after CDDP treatment. Salicylate significantly attenuated the CDDP-induced threshold shift from approximately 20 dB (at 16 and 24 kHz) to approximately 5 dB, and drastically reduced the loss of cochlear outer hair cells. Likewise, salicylate protected kidney function (measured as plasma blood urea nitrogen and creatinine levels) from CDDP toxicity. Protection of nerve conduction velocities of both sensory and motor nerves was minimal. The chemotherapeutic efficacy of CDDP on suppression of tumor mass and cancer cell metastasis remained unaffected by salicylate. The results suggest that administration of salicylate may become the basis of an effective therapeutic intervention against the ototoxic and nephrotoxic side effects associated with CDDP chemotherapy.",
author = "Geming Li and Sha, {Su Hua} and Elena Zotova and Arezzo, {Joseph C.} and {Van De Water}, {Thomas R.} and Jochen Schacht",
year = "2002",
doi = "10.1038/labinvest.3780453",
language = "English (US)",
volume = "82",
pages = "585--596",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action

AU - Li, Geming

AU - Sha, Su Hua

AU - Zotova, Elena

AU - Arezzo, Joseph C.

AU - Van De Water, Thomas R.

AU - Schacht, Jochen

PY - 2002

Y1 - 2002

N2 - Salicylate has recently been demonstrated to protect against the auditory and vestibular side effects of aminoglycoside antibiotics. Similarities in the toxic mechanisms suggest salicylate as a treatment strategy to prevent the ototoxic side effects of cisplatin (CDDP). We first tested protection of the inner ear in Wistar rats receiving a single infusion of 16 mg CDDP/kg body weight with or without treatment with 100 mg/kg salicylate (bid) for 5 days beginning one day before the CDDP infusion. Cisplatin induced a threshold shift of more than 30 dB (at 14 kHz; measured by auditory evoked brain stem response) that was significantly reduced by salicylate. We then examined the protective potential of salicylate on the cochlea, peripheral nerves, and kidney in a rat model of breast cancer-Fisher344 rats implanted with highly metastatic MTLn3 breast cancer cells. Animals received 3 × 5 mg CDDP/kg (given every third day), and salicylate was administered at 100 mg/kg (bid) from 2 days before to 3 days after CDDP treatment. Salicylate significantly attenuated the CDDP-induced threshold shift from approximately 20 dB (at 16 and 24 kHz) to approximately 5 dB, and drastically reduced the loss of cochlear outer hair cells. Likewise, salicylate protected kidney function (measured as plasma blood urea nitrogen and creatinine levels) from CDDP toxicity. Protection of nerve conduction velocities of both sensory and motor nerves was minimal. The chemotherapeutic efficacy of CDDP on suppression of tumor mass and cancer cell metastasis remained unaffected by salicylate. The results suggest that administration of salicylate may become the basis of an effective therapeutic intervention against the ototoxic and nephrotoxic side effects associated with CDDP chemotherapy.

AB - Salicylate has recently been demonstrated to protect against the auditory and vestibular side effects of aminoglycoside antibiotics. Similarities in the toxic mechanisms suggest salicylate as a treatment strategy to prevent the ototoxic side effects of cisplatin (CDDP). We first tested protection of the inner ear in Wistar rats receiving a single infusion of 16 mg CDDP/kg body weight with or without treatment with 100 mg/kg salicylate (bid) for 5 days beginning one day before the CDDP infusion. Cisplatin induced a threshold shift of more than 30 dB (at 14 kHz; measured by auditory evoked brain stem response) that was significantly reduced by salicylate. We then examined the protective potential of salicylate on the cochlea, peripheral nerves, and kidney in a rat model of breast cancer-Fisher344 rats implanted with highly metastatic MTLn3 breast cancer cells. Animals received 3 × 5 mg CDDP/kg (given every third day), and salicylate was administered at 100 mg/kg (bid) from 2 days before to 3 days after CDDP treatment. Salicylate significantly attenuated the CDDP-induced threshold shift from approximately 20 dB (at 16 and 24 kHz) to approximately 5 dB, and drastically reduced the loss of cochlear outer hair cells. Likewise, salicylate protected kidney function (measured as plasma blood urea nitrogen and creatinine levels) from CDDP toxicity. Protection of nerve conduction velocities of both sensory and motor nerves was minimal. The chemotherapeutic efficacy of CDDP on suppression of tumor mass and cancer cell metastasis remained unaffected by salicylate. The results suggest that administration of salicylate may become the basis of an effective therapeutic intervention against the ototoxic and nephrotoxic side effects associated with CDDP chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0036091647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036091647&partnerID=8YFLogxK

U2 - 10.1038/labinvest.3780453

DO - 10.1038/labinvest.3780453

M3 - Article

C2 - 12003999

AN - SCOPUS:0036091647

VL - 82

SP - 585

EP - 596

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 5

ER -